XEDEN 150mg

Main information

  • Trade name:
  • XEDEN 150mg
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • XEDEN 150mg
    Austria
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • enrofloxacin
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0186/003
  • Authorization date:
  • 30-09-2010
  • EU code:
  • FR/V/0186/003
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

VETERINARYMEDICINALPRODUCT

XEDEN150mgtabletfordogs

PARTIB

SUMMARYOFPRODUCTCHARACTERISTICS

PharmaceuticalForm

Tablet

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

XEDEN150mgtabletfordogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Onetabletcontains:

Enrofloxacin..........................................................150.0mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet

Clover-shapedscoredbeigetablet

Thetabletcanbedividedintofourequalparts.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs

4.2 Indicationsforuse,specifyingthetargetspecies

Indogs:

-Treatmentoflowerurinarytractinfections(associatedornotwithprostatitis)andupper

urinarytractinfectionscausedbyEscherichiaColiorProteusmirabilis.

-Treatmentofsuperficialanddeeppyoderma.

4.3 Contraindications

Donotuseinyoungorgrowingdogs(dogsagedlessthan12months(smallbreed)orless

than18months(largebreed))astheproductmaycauseepiphysealcartilagealterationsin

growingpuppies.

Donotuseindogshavingseizuredisorders,sinceenrofloxacinmaycauseCNSstimulation.

Donotuseindogswithknownhypersensitivitytofluoroquinolonesortoanyoftheexcipients

oftheproduct.

Donotuseinthecaseofresistancetoquinolones,asthereexistsalmostcompletecross

resistancetootherquinolonesandcompletecrossresistancetootherfluoroquinolones.

Seealsosection4.7and4.8.

4.4Specialwarningsforeachtargetspecies

None

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhichhave

respondedpoorly,orareexpectedtorespondpoorly,tootherclassesofantimicrobials.

Whereverpossible,fluoroquinolonesshouldbeusedbasedonsusceptibilitytesting.

UseoftheproductdeviatingfrominstructionsgivenintheSPCmayincreasetheprevalence

ofbacteriaresistanttofluoroquinolonesandmaydecreasetheeffectivenessoftreatment

withotherquinolonesduetothepotentialforcrossresistance.

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccountwhentheproductis

used.

Usetheproductwithcautionindogswithsevererenalorhepaticimpairment.

Pyodermaismostlysecondarytoanunderlyingdisease.Itisadvisabletodeterminethe

underlyingcauseandtotreattheanimalaccordingly.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Incaseofaccidentalingestion,seekmedicaladviceimmediatelyandshowthepackage

leaflettothephysician.

Washhandsafterhandlingtheproduct.

Incaseofcontactwitheyes,rinseimmediatelywithplentyofwater.

4.6Adversereactions(frequencyandseriousness)

Possiblejointcartilagealterationsingrowingpuppies(see4.3contra-indications).

Inrarecasesvomitingandanorexiaareobserved.

Inrarecase,hypersensitivereactionsmayoccur.Inthiscase,theadministrationoftheproduct

shouldbestopped.

Neurologicalsigns(seizures,tremors,ataxia,excitation)canoccur..

4.7Useduringpregnancy,lactationorlay

Useduringpregnancy:Laboratorystudiesinlaboratoryanimals(rat,chinchilla)havenot

producedanyevidenceofateratogenic,foetotoxic,maternototoxiceffect.Useonly

accordingtothebenefit/riskassessmentbytheresponsibleveterinarian.

Useduringlactation:Asenrofloxacinpassesintothematernalmilk,theuseisnot

recommendedduringlactation.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Concurrentuseofflunixinshouldbeundercarefulveterinarymonitoring,astheinteractions

betweenthesedrugsmayleadtoadverseeventsrelatedtodelayedelimination.

Concomitantadministrationoftheophyllinerequirescarefulmonitoringasserumlevelsof

theophyllinemayincrease.

Concurrentuseofmagnesiumoraluminumcontainingsubstances(suchasantacidsor

sucralfate)mayreduceabsorptionofenrofloxacin.Thesedrugsshouldbeadministeredtwo

hoursapart.

Donotusewithtetracyclines,phenicolsormacrolidesbecauseofpotentialantagonistic

effects.

4.9 Amountstobeadministeredandadministrationroute

Oraluse

5mgofenrofloxacin/kg/dayasasingledailydosing,i.e.onetabletfor30kgdailyfor:

- 10daysinlowerurinarytractinfections

- 15daysinupperurinarytractinfectionsandlowerurinarytractinfectionsassociated

withprostatitis

- Upto21daysinsuperficialpyodermadependingonclinicalresponse

- Upto49daysindeeppyodermadependingonclinicalresponse

Thetreatmentshouldbereconsideredincaseoflackofclinicalimprovementathalfofthe

treatmentduration

XEDEN50mg

Numberoftabletsperday XEDEN150mg

Numberoftabletsperday Dogweight(kg)

¼ ≥2 - <4

½ ≥4 - <6.5

¾ ¼ ≥6.5 - <8.5

1 ¼ ≥8.5 - <11

1¼ ½ ≥11

- <13.5

1½ ½ ≥13.5 - <17

¾ ≥17

- <25

1 ≥25 - <35

1¼ ≥35

- <40

1½ ≥40 - <50

1¾ ≥50

- <55

2 ≥55 - <65

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyaspossibleto

avoidunderdosing.

Thetabletsareflavoured,andarewellacceptedbydogs.Thetabletsmaybeadministered

directlyinthemouthofthedogorsimultaneouslywithfoodifnecessary.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosingcancausevomitingandnervoussigns(muscletremor,incoordinationand

convulsions)whichmayrequiretreatmentdiscontinuation.

Intheabsenceofanyknownantidote,applydrugeliminationmethodsandsymptomatic

treatment.

Ifnecessary,administrationofaluminium-ormagnesium-containingantacidsoractivated

carboncanbeusedtoreduceabsorptionofenrofloxacin.

Accordingtoliterature,signsofoverdosagewithenrofloxacinindogssuchasinappetence

andgastrointestinaldisturbancewereobservedatapproximately10timestherecommended

dosewhenadministeredfortwoweeks.Nosignsofintolerancewereobservedindogs

administered5timestherecommendeddoseforamonth.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

ATCvetcode:QJ01MA90

Pharmacotherapeuticgroup:Fluoroquinolones

5.1 Pharmacodynamicproperties

Enrofloxacinisasyntheticfluoroquinoloneantibioticthatexertsitsactivitybyinhibiting

topoisomeraseII,anenzymeinvolvedinthemechanismofbacterialreplication.

Enrofloxacinexertsbactericidalactivityconcentration-dependantwithsimilarvaluesof

minimalinhibitconcentrationandminimalbactericideconcentrations.Italsopossesses

activityagainstbacteriainthestationaryphasebyanalterationofthepermeabilityofthe

outermembranephospholipidcellwall.

Ingeneral,enrofloxacinexhibitsgoodactivityagainstmostgram-negativebacteria,

especiallythoseoftheEnterobacteriacea.Escherichiacoli,Klebsiellaspp.,Proteusspp.,

andEnterobacterspp.aregenerallysusceptible.

Pseudomonasaeruginosaisvariablysusceptibleand,whenitissusceptible,usuallyhasa

higherMICthanothersusceptibleorganisms.

StaphylococcusaureusandStaphylococcusintermediususuallyaresusceptible.

Streptococci,enterococci,anaerobicbacteriacangenerallybeconsideredresistant.

Inductionofresistanceagainstquinolonescandevelopbymutationsinthegyrasegeneof

bacteriaandbychangesincellpermeabilitytowardsquinolones.

5.2Pharmacokineticparticulars

Enrofloxacinisrapidlymetabolisedtoformanactivecompound,ciprofloxacin.

AfteroraladministrationofXEDEN150(5mg/kg)indogs:

- Themaximalplasmaconcentrationofenrofloxacinof1.72µg/mLwasobservedone

hourfollowingadministration.

- Themaximalplasmaconcentrationofciprofloxacin(0.32µg/mL)wasobservedtwo

hoursfollowingadministration.

Enrofloxacinisprimarilyexcretedviathekidneys.Amajorportionoftheparentdrugandits

metabolitesisrecoveredinurine.

Enrofloxaciniswidelydistributedinthebody.Thetissueconcentrationsareoftenhigherthan

theserumconcentrations.Enrofloxacincrossestheblood-brainbarrier.Thedegreeof

proteinbindinginserumis14%indogs.Thehalf-lifeinserumis3-5hoursindogs(5mg/kg).

Approximately60%ofthedoseisexcretedasunchangedenrofloxacinandtheremainderas

metabolites,amongstothersciprofloxacin.Thetotalclearanceisapproximately9

ml/minute/kgbodyweightindogs.

Environmentalproperties

Notapplicable

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Pigliverpowder

Yeast

Cellulosemicrocrystalline

Croscarmellosesodium

Copovidone

Silicacolloidalanhydrous

Hydrogenatedcastoroil

Lactosemonohydrate

6.2Incompatibilities

Notknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:

3years

Shelf-lifeofdividedtablets:

72hours

6.4.Specialprecautionsforstorage

Storeintheoriginalcontainer

Protectfromlight

Thismedicinalproductdoesnotrequireanyspecialtemperaturestorageconditions.

Anydividedtabletsshouldbereturnedtotheoriginalblisterforstorage.

Anydividedtabletsremainingafter72hoursshouldbediscarded.

6.5Natureandcompositionofimmediatepackaging

Blistercomplex:PVDC-TE-PVC/Aluminiumheatsealedblisterswith6tablets/blister

Cardboardboxwith2blistersof6tablets

Cardboardboxwith20blistersof6tablets

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

SOGEVAL

200avenuedeMayenne

ZoneIndustrielledesTouches

53000LAVAL

France

Tel:33.2.43.49.51.51

Fax:33.2.43.53.97.00

e-mail: sogeval@sogeval.fr

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10 DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Tobecompletedinaccordancewithnationalrequirements.

30-10-2018

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP  75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a...

FDA - U.S. Food and Drug Administration

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

5-10-2018

Consumer Alert: Sprout Creek Farm “Margie” Cheese Batch Recalled

Consumer Alert: Sprout Creek Farm “Margie” Cheese Batch Recalled

Today the New York State Department of Agriculture and Markets alerted consumers to a pasteurization problem with one of Sprout Creek Farm's pasteurized cow's milk cheeses, "Margie," made on 8/28/2018. Sprout Creek Farm is located in Poughkeepsie, NY. The reason for the recall is the air temperature at the start and end of the pasteurization process is required to be above 150deg F per the Grade "A" Pasteurized Milk Ordinance; the batch in question did not meet that standard. The recall pertains only to...

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Vismodegib hard capsule 150 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

31-7-2018

Public Notification: Boss Rhino 15000 contains hidden drug ingredient

Public Notification: Boss Rhino 15000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Boss Rhino 15000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

19-7-2018

K9 Natural Ltd recalls K9 Natural Frozen Chicken Feast Raw Pet Food 11lb bags

K9 Natural Ltd recalls K9 Natural Frozen Chicken Feast Raw Pet Food 11lb bags

K9 Natural Ltd is voluntarily recalling K9 Natural Frozen Chicken Feast 11lb bags, batch number #150517, that were imported into the Canadian market in July 2017 because they have the potential to be contaminated with Listeria monocytogenes. No other K9 Natural products are affected in Canada.

Health Canada

29-6-2018

Nationaal Sportakkoord ondertekend

Nationaal Sportakkoord ondertekend

Ruim 700 extra buurtsportcoaches, verhoging van de onbelaste vrijwilligersvergoeding van €1500 naar €1700 euro per jaar, €87 miljoen aan subsidie voor sportverenigingen die investeren in accommodaties, een nieuwe code goed sportbestuur en beweegprogramma’s voor kinderen onder de 6 jaar. Dit is slechts een greep uit het sportakkoord dat minister Bruno Bruins (Sport)heeft gesloten met de sport, gemeenten en maatschappelijke organisaties en bedrijven. Het is de eerste keer dat zoveel partijen zijn samengebr...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

1-8-2017

Withdrawal of one more batch of counterfeit packs of the schizophrenia medicine Xeplion 150 mg

Withdrawal of one more batch of counterfeit packs of the schizophrenia medicine Xeplion 150 mg

German and Danish parallel importers and the Danish Medicines Agency are now withdrawing the fourth batch of Xeplion 150 mg from wholesale distributors, hospitals and pharmacies, because the batch contains counterfeit packs.

Danish Medicines Agency

27-7-2017

Counterfeit packs of the schizophrenia medicine Xeplion 150 mg

Counterfeit packs of the schizophrenia medicine Xeplion 150 mg

One German and several Danish parallel importers and the Danish Medicines Agency have withdrawn several batches of Xeplion 150 mg from wholesale distributors, hospitals and pharmacies, because the batches contained counterfeit packs.

Danish Medicines Agency

6-4-2017

More batches of EpiPen® are withdrawn

More batches of EpiPen® are withdrawn

MEDA has decided to withdraw four more batches of EpiPen®. The withdrawal concerns two batches of EpiPen® 300 micrograms/dose and two batches of EpiPen® Jr 150 micrograms/dose. The latter is used for acute hypersensitivity reactions in children. The reason for the withdrawal is that there is a risk that the auto-injector does not work.

Danish Medicines Agency

27-6-2018

EU/3/15/1590 (Merck Europe B.V.)

EU/3/15/1590 (Merck Europe B.V.)

EU/3/15/1590 (Active substance: Recombinant human monoclonal IgG1 antibody against programmed death ligand-1) - Transfer of orphan designation - Commission Decision (2018)4088 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/15/T/02

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1383 (IQVIA RDS Ireland Limited)

EU/3/14/1383 (IQVIA RDS Ireland Limited)

EU/3/14/1383 (Active substance: Single-chain urokinase plasminogen activator) - Transfer of orphan designation - Commission Decision (2018)3150 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/125/14/T/01

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1763 (IQVIA RDS Ireland Limited)

EU/3/16/1763 (IQVIA RDS Ireland Limited)

EU/3/16/1763 (Active substance: Tadekinig alfa) - Transfer of orphan designation - Commission Decision (2018)1825 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/16/T/01

Europe -DG Health and Food Safety